Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22831445 | 1.00 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL560686 | 1.00 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL9669985 | 0.98 | TSHR (0.55) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL20001268 | 0.81 | HTR3A (0.53) | TSHRALDH1A1CYP1A2CYP2C19PKM | |
| SCHEMBL20177606 | 0.81 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL20475320 | 0.81 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL10200945 | 0.81 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL481990 | 0.81 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL18590504 | 0.81 | TSHR (0.61) | TSHRPDE4AALDH1A1PDE4BPDE4C | |
| SCHEMBL1269697 | 0.81 | TSHR (0.57) | TSHRPDE4AALDH1A1PDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350245-B2 | Stable oral suspensions of baclofen | ANI PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | claimed |
| US-20240408042-A1 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | CLINICAL RES ASSOCIATES LLC (US) | 2024-12-12 | — | — | US | claimed |
| US-20240189229-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF BACLOFEN FOR ORAL ADMINISTRATION | ANI PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | claimed |
| US-20240173282-A1 | STABLE ORAL BACLOFEN COMPOSITIONS | ANI PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| US-11857524-B2 | Stable oral suspensions of baclofen | ANI PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20230285341-A1 | STABLE ORAL SUSPENSIONS OF BACLOFEN | SLAYBACK PHARMA LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20220347140-A1 | STABLE ORAL SUSPENSIONS OF BACLOFEN | SLAYBACK PHARMA LLC (US) | 2022-11-03 | — | — | US | claimed |
| US-11484518-B1 | Stable oral suspensions of baclofen | SLAYBACK PHARMA LLC (US) | 2022-11-01 | — | — | US | claimed |
| US-9474732-B2 | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products | MALLINCKRODT LLC (US) | 2016-10-25 | — | — | US | claimed |
| CN-105519550-A | Herbicide for coniferous nursery garden | YANTAI LONGSHUN CHEMICAL TECH CO LTD | 2016-04-27 | — | — | CN | claimed |
| US-20160058724-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-03-03 | — | — | US | claimed |
| US-9180108-B2 | Baclofen formulations and methods for making same | MEDTRONIC, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20150258279-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS AND RELATED DELIVERY SYSTEM | IMC EXPLORATION COMPANY | 2015-09-17 | — | — | US | claimed |
| US-20150105466-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS | HSBC BANK USA, NATIONAL ASSOCIATION | 2015-04-16 | — | — | US | claimed |
| US-8969414-B2 | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products | MALLINCKRODT LLC (US) | 2015-03-03 | — | — | US | claimed |
| US-20130109755-A1 | Baclofen Formulations and Methods for Making Same | MEDTRONIC, INC. (US) | 2013-05-02 | — | — | US | claimed |
| US-20100216887-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS | CNS THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | claimed |
| WO-2010090765-A2 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS | CNS THERAPEUTICS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173282-A1 | STABLE ORAL BACLOFEN COMPOSITIONS | SLC6A1, GABBR2, SLC6A13 | TSHR 4155/4885PDE4A 916/4885ALDH1A1 1950/4885 |
| US-20160058724-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | GABRE, GABRP, PLCB1 | TSHR 1917/4885PDE4A 551/4885ALDH1A1 3778/4885 |
| US-12350245-B2 | Stable oral suspensions of baclofen | GABBR2, SLC6A1, GABBR1 | TSHR 4217/4885PDE4A 786/4885ALDH1A1 1689/4885 |
| US-20240408042-A1 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | GABBR2, GABBR1, GABRB2 | TSHR 3951/4885PDE4A 384/4885ALDH1A1 3548/4885 |
| US-11484518-B1 | Stable oral suspensions of baclofen | GABBR2, SLC6A1, GABBR1 | TSHR 4217/4885PDE4A 786/4885ALDH1A1 1689/4885 |
| US-20240189229-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF BACLOFEN FOR ORAL ADMINISTRATION | GABBR2, SLC6A1, SLC6A13 | TSHR 3736/4885PDE4A 1158/4885ALDH1A1 3102/4885 |
| US-20220347140-A1 | STABLE ORAL SUSPENSIONS OF BACLOFEN | GABBR2, SLC6A1, GABBR1 | TSHR 4217/4885PDE4A 786/4885ALDH1A1 1689/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | TSHR 4715/4885PDE4A 1155/4885ALDH1A1 250/4885 |
| US-20150258279-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS AND RELATED DELIVERY SYSTEM | SLC6A11, SLC6A1, GABRB1 | TSHR 3097/4885PDE4A 2329/4885ALDH1A1 1614/4885 |
| US-20130109755-A1 | Baclofen Formulations and Methods for Making Same | GABRE, GABRP, PLCB1 | TSHR 1917/4885PDE4A 551/4885ALDH1A1 3778/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | TSHR 4715/4885PDE4A 1155/4885ALDH1A1 250/4885 |
| US-20150105466-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS | GABBR1, GABBR2, GABRB2 | TSHR 3951/4885PDE4A 906/4885ALDH1A1 1581/4885 |
| US-20100216887-A1 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS | GABBR1, GABBR2, GABRB2 | TSHR 4046/4885PDE4A 1154/4885ALDH1A1 1518/4885 |
| US-20230285341-A1 | STABLE ORAL SUSPENSIONS OF BACLOFEN | GABBR2, SLC6A1, GABBR1 | TSHR 4217/4885PDE4A 786/4885ALDH1A1 1689/4885 |
| US-11857524-B2 | Stable oral suspensions of baclofen | GABBR2, SLC6A1, GABBR1 | TSHR 4217/4885PDE4A 786/4885ALDH1A1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.